With 20+ years of experience in life sciences, biotech strategy, and oncology innovation, I support biotech teams in building stronger paths from scientific opportunity to clinical and business execution. My work focuses on combining AI, genomics, and precision medicine strategy to improve how therapies are developed, prioritized, and advanced.
I serve as President and CEO of Lantern Pharma, where I lead strategy across an AI-driven precision oncology pipeline and help shape how data-guided development can reduce risk, cost, and timelines in drug development. I also chair Starlight Therapeutics, a Lantern subsidiary focused on CNS and brain cancers.
My background includes leading Cancer Genetics as President and CEO, raising significant capital, scaling teams globally, and earlier work in corporate strategy, M&A, and advisory roles across biotech and technology. I help founders, investors, and leadership teams align scientific ambition with financing, partnerships, and practical execution in high-stakes therapeutic development.
